Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, DOXIL, and Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT00698451Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2008
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Johnson & Johnson. Primary endpoint: Objective Response Rate at 280 days. Started Aug 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00698451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698451.